Mi­crobes Aren't Mooks...

The Abid­ing Threat of An­tibi­otic Re­sis­tance

by Daniel

The phrase 'mook chivalry ' might not be  rec­og­nized by many of our read­ers, but the sit­u­a­tion it de­scribes will cer­tainly be fa­mil­iar: A hero faces a crowd of vil­lains who are ready to at­tack. Rather than all charg­ing si­mul­ta­ne­ously to over­whelm, they en­ter into the fight one at a time, po­litely wait­ing un­til the hero dis­patches with the present chal­lenge be­fore en­cum­ber­ing the hero with a new threat (Fig­ure 1).

Fig­ure 1. An ex­am­ple of mook chivalry that oc­curs dur­ing com­bat in the Fi­nal Fan­tasy video game fran­chise, as fea­tured in "What Video Game Back­ground Char­ac­ters Are Think­ing" and gen­er­ated by user Nin­ten­doLe­monz. Source

Though orig­i­nat­ing as a deroga­tory term, 'mook' has come to be a syn­onym for 'can­non-fod­der' to char­ac­ter­ize seem­ingly in­com­pe­tent masses of dis­pos­ably stan­dard-is­sue goons. Think of the tar­get-miss­ing Im­pe­r­ial Storm Troop­ers or Bat­tle Droids of Star Wars, for ex­am­ple. The cliché of mook chivalry has been par­o­died through­out me­dia, from the writ­ing of Terry Pratch­ett, to a Sat­ur­day Night Live skit, to a comedic, but dis­turbingly vi­o­lent, cafe­te­ria fight scene in an episode of Fam­ily Guy.

In re­al­ity, fisticuffs and rum­bles rarely pro­ceed with any such one-op­po­nent-at-a-time rule, and this holds true all the way to in­ci­dents of hu­man-mi­crobe ri­valry. The global pop­u­la­tion cur­rently re­mains cap­tive, with at­ten­tion riv­eted, to the SARS-CoV‑2 pan­demic and hopes for any/all of three promis­ing vac­cine can­di­dates. De­spite all fo­cus on the coro­n­avirus, some sci­en­tists (and the me­dia) pointed out that the sec­ond wave of COVID-19 in Eu­rope co­in­cided with the typ­i­cal start to the flu sea­son; they won­dered, how bad would it get if the hu­man pop­u­la­tion be­came hit with not just one, but two pan­demics, si­mul­ta­ne­ously.

Fig­ure 2. Cover of Su­per­bugs: An Arms Race Against Bac­te­ria, by William Hall, An­thony Mc­Don­nell, and Jim O'Neill, from Har­vard Uni­ver­sity Press. Source

Thank­fully, that doesn't seem to be oc­cur­ring, likely in part due to the use of masks and so­cial dis­tanc­ing for coro­n­avirus that would also help limit in­fluenza trans­mis­sion. But the gen­eral con­cern and point are valid. There is no chivalry among mi­crobes to chal­lenge us one at a time. While all our con­cern and ef­forts ramp up in re­sponse to coro­n­avirus, other mi­cro­bial threats are not sim­ply go­ing away or sit­ting aside as spec­ta­tors. Amid so­ci­etal dis­rup­tions brought on di­rectly by the pan­demic – or in­di­rectly through in­ept po­lit­i­cal lead­er­ship – vac­ci­na­tion rates against other viruses, such as measles, have been fur­ther on the de­cline. And with all that fo­cus on viruses, let us not for­get about the con­tin­ued emerg­ing fun­gal pathogens, or the abid­ing threat of an­tibi­otic re­sis­tance to bac­te­r­ial dis­ease out­comes.

Su­per­bugs: An Arms Race Against Bac­te­ria

Pub­lished by Har­vard Uni­ver­sity Press in 2018, Su­per­bugs by Hall, Mc­Don­nell, and O'Neill (Fig­ure 2) presents a well-doc­u­mented ar­gu­ment for why we should be con­cerned about an­tibi­otic re­sis­tance, with its rel­e­vance still ap­plic­a­ble here two years later. Ac­cord­ing to 2019 es­ti­mates from the CDC, ap­prox­i­mately 2.8 mil­lion in­fec­tions and 35,000 deaths oc­cur each year in the United States due to an­tibi­otic re­sis­tance. Glob­ally speak­ing, an­tibi­otic re­sis­tance claims an es­ti­mated 1.5 mil­lion deaths per year. While we ex­pect a sin­gle virus pan­demic to pass rel­a­tively soon, the harm from an­tibi­otic re­sis­tance could con­tinue from decades past through decades fu­ture, wors­en­ing to a point where cur­rently treat­able bac­te­r­ial in­fec­tions could con­ceiv­ably re­take their place from can­cer as the num­ber one killer of hu­mans.

Now, to bor­row a clever al­lit­er­a­tion from Mark Mar­tin: all this might be preach­ing to the prokary­otic choira bit here. Our read­ers are prob­a­bly aware of an­tibi­otic re­sis­tance from the his­tor­i­cal, med­ical, eco­log­i­cal, cell bi­o­log­i­cal, and mol­e­c­u­lar per­spec­tives. A 2008 post by Joshua Fierer high­lighted the good and the bad that an­tibi­otics have brought us, and four years later a post by Mar­vin Fried­man cov­ered as­pects of the evo­lu­tion of re­sis­tance.
 

Fig­ure 3. An­nual de­crease in global GDP (es­ti­mated) re­sult­ing from in­creases in rates of an­timi­cro­bial re­sis­tance, as pre­sented in Fig­ure 2.2 of Su­per­bugs. Sources: World Bank and the Re­view on An­timi­cro­bial Re­sis­tance

For those not versed in the re­al­i­ties of mi­cro­bial drug re­sis­tance, the first two chap­ters of Su­per­bugs cover the es­sen­tial de­tails, from the dis­cov­ery of an­tibi­otics to the al­most im­me­di­ate ap­pre­ci­a­tion of bac­te­r­ial re­sis­tance. The au­thors cover the ba­sic mi­cro­bi­ol­ogy along­side a brief his­tor­i­cal nar­ra­tive on the birth of germ the­ory and an out­line of the gen­eral mech­a­nisms of re­sis­tance. They fo­cus most of their at­ten­tion in their in­tro­duc­tion on the so­ci­etal con­se­quences of an­tibi­otic use on bac­te­r­ial bi­ol­ogy. They sum­ma­rize and re­view stud­ies that help quan­tify both the de­gree of the re­sis­tance prob­lem and the costs it en­gen­ders, both eco­nomic and hu­man (Fig­ure 3).

The third chap­ter closes out the in­tro­duc­tory part with an ar­gu­ment of why so­ci­ety has thus far failed to tackle the prob­lem of in­creased an­tibi­otic-re­sis­tant in­fec­tions. They use data from stud­ies and in­ter­views with sci­en­tists and med­ical pro­fes­sion­als to de­scribe three fac­tors that have played into the dif­fi­culty of deal­ing with an­tibi­otic re­sis­tance: the dif­fi­culty of the sci­ence in­volved, failed eco­nomic mod­els, and aca­d­e­mic dis­en­gage­ment. The au­thors then con­clude that "an in­fec­tion with an­tibi­otic re­sis­tant bac­te­ria is only the last step in a long chain of events." To set up the sec­ond part of their book, they de­scribe how this is anal­o­gous to Markov chains used by econ­o­mists and other sta­tis­ti­cians to pre­dict out­comes and model in­ter­ven­tions. The au­thors ar­gue that a fo­cus on treat­ing an­tibi­otic re­sis­tant in­fec­tions rep­re­sents a short-term strat­egy that fails to im­pact ear­lier el­e­ments in the chain such as in­fec­tion, trans­mis­sion, or the co­pi­ous de­po­si­tion of an­timi­cro­bials into the en­vi­ron­ment.

What Econ­o­mists Learned from Mi­cro­bi­ol­ogy and What Mi­cro­bi­ol­o­gists Can Learn from Them

As you have likely gath­ered by now, Su­per­bugs isn't like other books that fo­cus on the mi­cro­bi­ol­ogy sur­round­ing an­tibi­otic re­sis­tance. The au­thors come from back­grounds out­side of bi­ol­ogy. In 2014 they took part in an eco­nomic Re­view on An­timi­cro­bial Re­sis­tance. Econ­o­mist Jim O'Neill served as chair of that com­mit­tee, and his two coau­thors of Su­per­bugs, William Hall and An­thony Mc­Don­nell were also mem­bers as se­nior pol­icy ad­vi­sor and head of eco­nomic re­search, re­spec­tively.

Su­per­bugs there­fore gives an outsider's per­spec­tive on microbiological/medical is­sues and cen­ters on propos­ing a wide range of so­lu­tions to the prob­lem of an­tibi­otic re­sis­tance rather than just sum­ma­riz­ing the prob­lem and its mech­a­nisms. The en­tire sec­ond part of the book, in five chap­ters, tack­les that broad ques­tion of what best to do now for the fu­ture.

Chap­ter 4 dis­cusses in­cen­tives that could be im­ple­mented for new an­tibi­otic de­vel­op­ment. One ex­am­ple they in­tro­duce is the Com­bat­ing An­tibi­otic Re­sis­tant Bac­te­ria Biopharmaceu­tical Ac­cel­er­a­tor (CARB‑X) ini­tia­tive at Boston Uni­ver­sity School of Law, sup­ported through the Bio­med­ical Ad­vanced Re­search and De­vel­op­ment Au­thor­ity agency and the Well­come Trust. This pub­lic-pri­vate part­ner­ship was formed to fund clin­i­cal tri­als of promis­ing novel an­tibi­otics in a way that aims to min­i­mize 'group-think' by hav­ing many smaller group part­ners make de­ci­sions rather than one large en­tity alone. The au­thors quote Kevin Out­ter­son, the CEO, re­gard­ing how even well-mean­ing in­di­vid­u­als can waste money on failed re­search: "If we know any­thing from his­tory, it is that com­pe­tent com­pa­nies can make ter­ri­ble de­ci­sions."

Re­turn­ing to their Markov chain anal­ogy at the end of the first part, the au­thors then delve deeper into ar­gu­ments that pre­ven­tion of an­tibi­otic re­sis­tant in­fec­tion is prefer­able to find­ing ways to deal with them af­ter they oc­cur. In a pas­sage that be­gins with a quote from Val Cur­tis, the di­rec­tor of the Hy­giene Cen­tre at the Lon­don School of Hy­giene and Trop­i­cal Med­i­cine, the au­thors write:  

""Drug-re­sis­tant in­fec­tions are a re­sult of in­fec­tion, so if peo­ple weren't get­ting in­fected, they wouldn't need the drugs, and then we wouldn't get an­tibi­otic re­sis­tance." It is much eas­ier to solve most prob­lems, in­clud­ing that of drug-re­sis­tant bac­te­ria, by pre­vent­ing them be­fore they start. The power of pre­ven­tion was ap­par­ent dur­ing the out­breaks of Ebola and SARS, for which there was no ef­fec­tive treat­ment. These two dis­eases were greatly con­strained and even­tu­ally de­feated by pre­ven­ta­tive mea­sures."

They pro­pose that things like bet­ter san­i­ta­tion, im­proved in­fec­tion con­trol, and pre­ven­ta­tive med­i­cines would en­able greater suc­cess. Even sim­ple things, like hand-wash­ing make a huge dif­fer­ence, yet are largely not rou­tinely fol­lowed. They cite a study of hand­wash­ing where 99% of those in­ter­viewed af­ter us­ing high­way rest-stop bath­rooms in the UK said that they had washed their hands with soap. How­ever, elec­tronic mon­i­tors in­di­cated that less than half had ac­tu­ally done so (64% of women and an abysmal 32% of men).

Fol­low­ing into the next chap­ter on re­duc­ing an­tibi­otic use, the au­thors ad­dress one of the largest hur­dles to im­ple­ment­ing their rec­om­mended mea­sures: the dif­fi­culty of chang­ing In­grained hu­man habits.

"It is much eas­ier to con­vince some­one to get a test for HIV, for ex­am­ple, than it is to con­vince them to al­ways wear a con­dom dur­ing sex, or to wash their hands. Any cam­paign should thus fo­cus on the min­i­mal be­hav­ioral change nec­es­sary to achieve the de­sired ef­fect. The best cam­paigns are based on emo­tions and peer pres­sure rather than facts." 

They then de­scribe a suc­cess­ful cam­paign in In­dia that changed be­hav­ior through sto­ries fea­tur­ing a kindly mother char­ac­ter who dis­played good hy­giene and child care, con­trasted with a dirty, dis­lik­able male char­ac­ter. I am re­minded of the Ger­man Der Struwwelpeter sto­ries my par­ents would haul out to en­cour­age me in hy­giene!

These Mea­sures aren't Just Ap­plic­a­ble to Bac­te­ria and An­tibi­otics

It bears re­turn­ing to the two quotes above with the re­al­iza­tion that they say some­thing not just about drug re­sis­tance or bac­te­r­ial in­fec­tions alone, but hold rel­e­vance for the broad is­sue of pre­vent­ing any health­care prob­lem ver­sus the short-term mis­take of only deal­ing with it af­ter the fact through treat­ment. We see the same is­sues now with SARS-CoV‑2. 

The power of pre­ven­tion in­deed was in­stru­men­tal in con­trol­ling Ebola and the first SARS. How­ever, they've also re­turned, and boy has the new SARS. But they have hardly been 'de­feated.' In fact, that com­pla­cency and a break­down in con­tin­ued pre­ven­ta­tive mea­sures and re­search likely aug­mented its un­wel­come re­boot. Even af­ter ini­tial out­break and spread, con­tin­ued re­fusals to face re­al­ity and im­ple­ment pre­ven­ta­tive mea­sures let us get to where we are now, cer­tainly in the U.S.A. As This Week in x‑ologypod­cast host Vin­cent Racaniello re­cently tweeted, "The head­lines are say­ing that an early mu­ta­tion MIGHT have made #SARS-CoV‑2 harder to stop. I think more blame should be as­cribed to hu­man stu­pid­ity." 

In a sim­i­lar vein, can one now read the sec­ond quoted para­graph above on the dif­fi­cul­ties of chang­ing in­grained be­hav­iors with­out think­ing about anti-maskers? The sim­i­lar­i­ties be­tween our cur­rent vi­ral predica­ment and the still-present an­tibi­otic re­sis­tance predica­ment sug­gest, based on the Su­per­bugs author's ar­gu­ments, that com­mon so­lu­tions ex­ist and these could be the best fo­cus for gen­eral pro­tec­tion of hu­mans from mi­cro­bial threats.

Next Steps

In the eighth, and fi­nal, chap­ter of Su­per­bugs, the au­thors sum­ma­rize their con­clu­sions and pro­pose the next steps for com­bat­ing an­tibi­otic re­sis­tance, stress­ing in their fi­nal para­graphs that this is "A Prob­lem That Can Be Solved." Their pro­pos­als are not par­tic­u­larly sur­pris­ing: education/awareness, eco­nomic in­cen­tives, po­lit­i­cal en­gage­ment, and above all co­or­di­na­tion be­tween di­verse groups/fields/expertise. This in­cludes the agri­cul­tural in­dus­try, the fo­cus of chap­ter 7, which has had as much (if not more) of an im­pact on ris­ing an­tibi­otic re­sis­tance than the med­ical in­dus­try. 

Even if not shock­ingly novel con­clu­sions in gen­eral, they are help­ful to see spelled out con­cisely af­ter the bulk of the book that has re­viewed spe­cific ex­am­ples of ac­tions to con­tinue ex­plor­ing or ex­pand. Those who are in­ter­ested in this topic, but might not know as much from the eco­nomic and po­lit­i­cal per­spec­tive as the mi­cro­bi­o­log­i­cal, will find Su­per­bugs an im­mensely read­able and in­dis­pens­able re­source. It has re­minded me that mi­crobes are never go­ing to act like mooks. It's im­por­tant that hu­mans don't act like mooks ei­ther, or else we won't do well in the in­evitable bi­o­log­i­cal con­flicts that arise through our in­ter­ac­tions.

Su­per­bugs: An Arms Race Against Bac­te­ria
By William Hall, An­thony Mc­Don­nell, and Jim O'Neill
Har­vard Uni­ver­sity Press, 2018, 246 pp.
ISBN: 9780674975989

 

Other Posts